Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai ReBone Biomaterials is a Chinese medical technology company focused on the development and manufacture of advanced bioactive materials for bone tissue engineering. Established in 2004 and rooted in research from the East China University of Science and Technology, the company specializes in synthetic bone graft substitutes and calcium phosphate cements. Its core products are designed to treat bone defects resulting from trauma, tumors, or degenerative diseases by providing a scaffold that promotes natural bone regeneration. ReBone's technology platform emphasizes biomimetic properties, allowing for high biocompatibility and controlled degradation rates. The company serves multiple clinical fields, including orthopedics, dentistry, and neurosurgery, and holds numerous patents in the field of inorganic biomaterials. As a leader in the Chinese domestic market, ReBone continues to innovate in the space of regenerative medicine and hard tissue repair.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai ReBone Biomaterials.